Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, current chief
Read morePharmaceutical Company News
The latest news from the pharmaceutical sector. Covering the latest breaking news, encompassing company news from leading pharmaceutical companies and related companies.
Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)
– Incyte announces launch of “Rare Reflections: MPNs Unmasked” as part of its ongoing efforts to raise awareness of MPNs
Read moreOtsuka Pharmaceutical Establishes Subsidiary in Malaysia｜News Releases | Otsuka Pharmaceutical Co., Ltd.
February 27, 2020 Otsuka Pharmaceutical Co., Ltd. Pharmaceuticals Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the establishment of a new subsidiary,
Read moreMallinckrodt to Present New Data from two Studies on Acthar® Gel (Repository Corticotropin Injection) Therapy in Multiple Sclerosis (MS) Relapse at Fifth Annual ACTRIMS Forum 2020
STAINES-UPON-THAMES, United Kingdom, Feb. 27, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it
Read moreAnti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for Approval in Japan – Media & Investors
For Immediate Release 2020.02.27 UCB Japan Co., Ltd.DAIICHI SANKYO Company, Limited Anti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for
Read moreEuropean Medicines Agency accepts submission of GSK’s Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer | GSK
Issued: London, UK GlaxoSmithKline plc announced that the European Medicines Agency (EMA) has validated the company’s Type II Variation (T2V)
Read moreIntroducing New UL·OS Face & Body Sheet A single sheet provides convenient facial and body care｜News Releases | Otsuka Pharmaceutical Co., Ltd.
Based on the unique concept of Cosmedics (cosmetics + medicine) aiming to promote healthy skin, Otsuka Pharmaceutical launched the UL·OS
Read moreFDA Advisory Committee Votes in Favor of Lilly’s CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer | Eli Lilly and Company
INDIANAPOLIS, Feb. 26, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that a U.S. Food and Drug
Read moreJohnson & Johnson to Participate in Barclays Global Healthcare Conference
New Brunswick, NJ (February 26, 2020) — Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global Healthcare Conference
Read moreAmgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 26, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier
Read moreVertex to Present at the Cowen Health Care Conference on March 3 | Vertex Pharmaceuticals
BOSTON–(BUSINESS WIRE)–Feb. 25, 2020– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care
Read moreTakeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
Osaka, Japan, February 26, 2020–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the
Read moreVertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand | Vertex Pharmaceuticals
LONDON–(BUSINESS WIRE)–Feb. 25, 2020– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients
Read moreLaunch of “Health Support Plus” Service to manage workforce health based on desknet’s NEO groupware｜News Releases | Otsuka Pharmaceutical Co., Ltd.
February 26, 2020 Otsuka Pharmaceutical Co., Ltd. Nutraceuticals Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Tatsuo Higuchi) and
Read moreJohnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of
Read moreFDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving
Read moreNovartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing
Read moreMallinckrodt plc Reports Strong Fourth Quarter and 2019 Results
STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the
Read moreMallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities
STAINES-UPON-THAMES, United Kingdom, Feb. 25, 2020 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK) (“Mallinckrodt” or the “Company”) today announced that the Company
Read moreAstraZeneca divests global rights to Movantik
25 February 2020 07:00 GMT License to RedHill Biopharma supports AstraZeneca’s focus on main therapy areas AstraZeneca has agreed to
Read moreWhole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars SOYJOY Peanuts Renewal Launch｜News Releases | Otsuka Pharmaceutical Co., Ltd.
February 25, 2020 Otsuka Pharmaceutical Co., Ltd. Nutraceuticals Otsuka Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan; President: Tatsuo Higuchi) has
Read moreEisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China | News Release：2020
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and FUJI YAKUHIN CO., LTD. (Headquarters: Saitama, CEO: Masayuki Takayanagi, “FUJI
Read moreU.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer | GSK
Issued: London, UK GlaxoSmithKline plc today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s submission of
Read moreSanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)
Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*) New major API company1 would secure
Read moreTakeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer
– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – Prescription Drug User Fee
Read more